[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354962-105":59,"doc-detail-354962-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","considerations-for-the-use-of-targeted-fluorescence-contrast-agents-to-detect-circulating-cancer-cell-populations-with-diffuse-in-vivo-flow-cytometry","Considerations for the use of targeted fluorescence contrast agents to detect circulating cancer cell populations with diffuse in vivo flow cytometry","","Metastasis drives most cancer-related deaths through disseminated circulating tumor cells (CTCs) that seed tumors at distant sites. Liquid-biopsy approaches based on small blood volumes and marker-driven flow cytometry can misestimate CTC burden and cannot track CTC changes over time. Fluorescence-guided, noninvasive in vivo enumeration could improve accuracy, but requires CTC-specific contrast agents. This study evaluates targeted fluorescence agents using in vitro and murine models.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/considerations-for-the-use-of-targeted-fluorescence-contrast-agents-to-detect-circulating-cancer-cell-populations-with-diffuse-in-vivo-flow-cytometry/354962/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/considerations-for-the-use-of-targeted-fluorescence-contrast-agents-to-detect-circulating-cancer-cell-populations-with-diffuse-in-vivo-flow-cytometry/354962.png","ImageObject",300,407,{"name":92,"@type":93},"Olivia Brown","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why do liquid-biopsy methods for CTC enumeration have accuracy limits?","Question",{"text":112,"@type":113},"CTCs are rare and only a small fraction of total blood volume is sampled, which can reduce sensitivity and quantitative accuracy. Short half-life and circadian variation also cause CTC counts to fluctuate over time, and sampling location relative to tumors and draining vessels can change results.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is the goal of using targeted fluorescence contrast agents for CTCs?",{"text":117,"@type":113},"To enable noninvasive fluorescence enumeration of CTCs directly in vivo. Achieving this requires contrast agents with sufficient CTC specificity to label CTCs while minimizing background fluorescence from non-cancer blood cells.",{"name":119,"@type":110,"acceptedAnswer":120},"How did the evaluated contrast agents perform in the study?",{"text":121,"@type":113},"All tested agents showed strong uptake and labeling by target cell lines but also produced small yet significant labeling of non-cancer blood cells. Rapid clearance and a fluorogenic approach reduced nonspecific interfering background signals, but none achieved the required high specificity, leading to false-positive CTC counts.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354962,1790167355,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","RESEARCH PAPER  \nConsiderations forthe use of targeted fluorescence contrast agents to detect circulating cancer cell populations with diffuse in vivo flow cytometry  \nJoshua S. Pace  ,a Grace Matheson,a Gauri Malankar  ,b Lei Wang  ,b,c  \nMelissa H. Wong,c,d Summer L. Gibbs  ,b,c and Mark Niedrea,*  \naNortheastern University, Department of Bioengineering, Boston, Massachusetts, United States bOregon Health and Sciences University (OHSU), Department of Biomedical Engineering, Portland,  \nOregon, United States  \ncOHSU, Knight Cancer Institute, Portland, Oregon, United States dOHSU, Department of Cell, Developmental and Cancer Biology, Portland, Oregon, United States  \nABSTRACT. Significance: Metastasis is a leading cause of cancer-related deaths. Disseminated circulating tumor cells (CTCs) through the bloodstream seed metastatic tumors at distant sites. Most methods for enumerating CTCs in humans clinically rely on drawing and analyzing small blood samples, but these may yield inaccurate estimates of CTC burden and cannot measure CTC changes over time. Identification and enumeration of CTCs for experimental or clinical purposes largely rely on marker-driven analyses by flow cytometry.  \nAim: In principle, noninvasive fluorescence enumeration of CTCs directly in vivo could provide a more accurate method for enumerating CTCs. However, this will require a specific contrast agent for CTCs. The goal of this work is to define characteristics of useful CTC contrast agents and perform preliminary testing of candidate contrast agents used for fluorescence-guided surgery (FGS) .  \nApproach: We evaluated a clinical small-molecule folate receptor–targeted molecular imaging agent (OTL38, pafolacianine), a fluorogenic pan-cathepsin imaging agent (VGT-309, abenacianine), and a set of custom-designed, small-molecule prostate-specific membrane antigen (PSMA)–targeted fluorophores. We tested these contrast agents using in vitro cell culture models and in in vivo murine models.  \nResults: All tested contrast agents showed not only high uptake and labeling by target cell lines but also small but significant labeling of non-cancer blood cells. Contrast agents that exhibited rapid clearance from circulation and the fluorogenic approach resulted in significantly reduced non-specific interfering background fluorescence signals.  \nConclusions: Although all of the tested targeted fluorescence contrast agents have properties useful for labeling of CTCs, thus far, none has exhibited the required high specificity. This resulted in some labeling of non-cancer blood cells, which presented false-positive CTC counts. Improved contrast agent design and multiplexed use of more than one contrast agent may improve this specificity.  \n© The Authors. Published by SPIE under a Creative Commons Attribution 4.0 International License. Distribution or reproduction of this work in whole or in part requires full attribution of the original publication, including its DOI. [DOI: 10.1117/1.JBO.31.2.027001]  \nKeywords: in vivo labeling; circulating tumor cell; targeted fluorescent contrast agents  \nPaper 250276GR received Sep. 2, 2025; revised Jan. 9, 2026; accepted Jan. 12, 2026; published Jan.  \n27, 2026 .  \n*Address all correspondence to Mark Niedre, [m.niedre@northeastern.edu](m.niedre@northeastern.edu)  \nJournal of Biomedical Optics 027001-1 February 2026 • Vol. 31(2)  \nPace et al.: Considerations for the use of targeted fluorescence contrast agents. . .  \n1 Introduction  \nMetastasis is the spread of cancer from the primary tumor to distant organs or tissues and is the primary cause of cancer-related mortality.1,2 One of the main pathways is hematogenous metastasis, wherein circulating tumor cells (CTCs) disseminate through the bloodstream. A small fraction may form secondary metastases.3–11 As such, CTCs are clinically significant and a focus of basic cancer research for over two decades.5,6, 12, 13  \nThe gold standard for enumerating and characterizing CTCs is “liquid b","cbCailMYnhOQdrHf","https://ap.wps.com/l/cbCailMYnhOQdrHf","pdf",9591466,21,"English","# Abstract\n# 1 Introduction\n## Metastasis and circulating tumor cells\n## Liquid biopsy and current limitations\n## Diffuse in vivo Flow Cytometry (DiFC) and optical alternatives","[{\"question\":\"Why do liquid-biopsy methods for CTC enumeration have accuracy limits?\",\"answer\":\"CTCs are rare and only a small fraction of total blood volume is sampled, which can reduce sensitivity and quantitative accuracy. Short half-life and circadian variation also cause CTC counts to fluctuate over time, and sampling location relative to tumors and draining vessels can change results.\"},{\"question\":\"What is the goal of using targeted fluorescence contrast agents for CTCs?\",\"answer\":\"To enable noninvasive fluorescence enumeration of CTCs directly in vivo. Achieving this requires contrast agents with sufficient CTC specificity to label CTCs while minimizing background fluorescence from non-cancer blood cells.\"},{\"question\":\"How did the evaluated contrast agents perform in the study?\",\"answer\":\"All tested agents showed strong uptake and labeling by target cell lines but also produced small yet significant labeling of non-cancer blood cells. Rapid clearance and a fluorogenic approach reduced nonspecific interfering background signals, but none achieved the required high specificity, leading to false-positive CTC counts.\"}]","Considerations for the use of targeted fluorescence contrast agents to detect circulating cancer cell populations with diffuse in vivo flow cytometry | PDF",1790115097,53,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/15b9ae491bd3b33d2a928e4b2762ef92.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5a4a479fda20ef89ccc137a76b483bfd.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c9cff2af51c591e8a8936760e0aa7b4c.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/76c4631b81e531b99854a03923931d49.webp",980,1268]